Lp(a)-Targeting Drugs Advance in Phase 3 Trials as Novartis Leads Market Push
Late-stage trials of Lp(a)-specific therapies are nearing completion with potential to address an unmodifiable genetic risk factor. Market entry will depend on outcome data, pricing negotiations and payer willingness to cover a high-prevalence condition. Evidence remains preliminary until cardiovascular outcome results are published.
Regulatory filings hinge on 2026-2027 readout of Lp(a)HORIZON and parallel siRNA trials. Payers will demand subgroup data showing benefit beyond LDL-C lowering and may restrict coverage to the highest-risk quartile. Real-world evidence registries will be needed post-approval to confirm whether Lp(a) reduction translates to population-level declines in myocardial infarction and revascularization.
Novartis: Lp(a)HORIZON primary endpoint met with ≥20% MACE reduction by Q4 2026
Sources (3)
- [1]Primary Source(https://www.statnews.com/2026/08/26/lp-a-drugs-novartis-amgen-lilly-potential-heart-disease-blockbuster/)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2030184)
- [3]Supporting Source(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01423-9/fulltext)